AIG
PRVL

American International Group’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

American International Group’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-8,301
Closed -$192 – 3197
2020
Q4 		$192 Sell
8,301
-238
-3% -$3.02K ﹤0.01% 2308
2020
Q3 		$87K Sell
8,539
-194
-2% -$2.6K ﹤0.01% 2602
2020
Q2 		$130K Buy
8,733
+426
+5% +$6.56K ﹤0.01% 2364
2020
Q1 		$101K Buy
8,307
+3,662
+79% +$58.3K ﹤0.01% 2300
2019
Q4 		$74K Sell
4,645
-39
-0.8% -$497 ﹤0.01% 2767
2019
Q3 		$58K Buy
+4,684
New +$53.1K ﹤0.01% 2858

American International Group's PRVL Position: Q1 2021 in Review

American International Group sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 8,301 shares — an estimated $192 sold.

American International Group first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $130K in Q2 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • American International Group reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • American International Group sold 8,301 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $192.
  • American International Group first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
  • American International Group's Prevail Therapeutics Inc. Common Stock position peaked at $130K in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on American International Group's 13F filing for Q1 2021, filed 7 May 2021.